Improved pharmaceutical formulation containing an HMG-CoA reductase inhibitor and method for the preparation thereof

Details for Australian Patent Application No. 2007355452 (hide)

Owner Pharmathen S.A.

Inventors Bikiaris, Dimitrios; Samara, Vicky; Ioannidou, Elli; Koutris, Efthimios; Karavas, Evangelos

Agent Spruson & Ferguson

Pub. Number AU-B-2007355452

PCT Pub. Number WO2009/000286

Filing date 25 June 2007

Wipo publication date 31 December 2008

Acceptance publication date 15 December 2011

International Classifications

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Event Publications

14 January 2010 PCT application entered the National Phase

  PCT publication WO2009/000286 Priority application(s): WO2009/000286

4 February 2010 Amendment Made

  The nature of the amendment is: Amend the applicant name from Parmatheen S.A. to Pharmathen S.A

15 December 2011 Application Accepted

  Published as AU-B-2007355452

12 April 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007355462-TPP II inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection

2007355422-Apparatus and method for electrical stimulation of human neurons